Loading...

EDSA EDESA BIOTECH INC Expansion Plans 8-K Filing

DS B

DS

EDESA BIOTECH INC

(EDSA)

2025 8-K

Positive Study Results

Financial Results

Share Offer Increase

Financial Results Released

Positive Study Results

Funding Agreement Amendment

Prospectus Supplement Filed

Equity Offerings

Financial Statements

Management Changes

Financial Results

Financial Results

Capital Structure Change

Share Offering Agreement

Earnings Release

Drug Candidate Selected for...

Annual Meeting Approval

Earnings Release

Earnings Release

Earnings Release

Compliance with Minimum Bid...

Credit Agreement with Parde...

Agreement with Government o...

Default in Payments

Earnings Release

Appointment of CFO

Notice of Delisting

Departure of Directors or C...

Earnings Release

Equity Distribution Agreement

FDIC Control of Silicon Val...

Earnings Release

External Links:

Edesa Biotech, Inc. announced on October 8, 2025, successful Phase 3 study results showing that its drug paridiprubart significantly reduced mortality in ARDS patients by 13% compared to placebo, leading to improved patient outcomes.

AI Assistant

EDESA BIOTECH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.